price
About
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
- Stock ticker
- CAI
- Company
- Caris Life Sciences, Inc.
- Industry
- Healthcare
- Category
- US
- Stock split / reverse split
- --
- Launch date
- Jun 18, 2025
- Listed exchange
- NASDAQ
Financials
Summary: CAI reported Revenue of 263.71M (+45.38%), beating expectations; EPS of -0.00 (+99.57%), missing expectations.
CAI conversion tables
 |  |
|---|---|
| 0.5 CAI | 18.02 SGD |
| 1 CAI | 36.05 SGD |
| 5 CAI | 180.28 SGD |
| 10 CAI | 360.57 SGD |
| |
|---|---|
| 0.5 SGD | 0.013867 CAI |
| 1 SGD | 0.027733 CAI |
| 5 SGD | 0.13867 CAI |
| 10 SGD | 0.27733 CAI |
More to explore
FAQ
CAI is trading at S$36.06, -0.56% over the last 24 hours. Track live moves on the price chart at the top of this page.
The CAI stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. CAI is currently trading at S$36.06, -0.56% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on CAI price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Healthcare sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. CAI's P/E ratio is currently 79.54 — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from CAI; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against CAI's historical range and other companies in the Healthcare sector.
Caris Life Sciences, Inc.'s market cap is currently 10.29B SGD. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.